We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
POOL icon
151
Pool Corp
POOL
$6.7B
$736K 0.01%
2,200
– –
VAR
152
DELISTED
Varian Medical Systems, Inc.
VAR
$705K 0.01%
4,100
– –
MTD icon
153
Mettler-Toledo International
MTD
$26.8B
$676K 0.01%
700
– –
JD icon
154
JD.com
JD
$40.8B
$675K 0.01%
8,700
– –
WSO icon
155
Watsco Inc
WSO
$14.9B
$652K 0.01%
2,800
– –
A icon
156
Agilent Technologies
A
$39.1B
$626K 0.01%
6,200
– –
SPGI icon
157
S&P Global
SPGI
$126B
$613K 0.01%
1,700
– –
EA icon
158
Electronic Arts
EA
$52.4B
$609K 0.01%
4,670
– –
MTCH icon
159
Match Group
MTCH
$8.84B
$606K 0.01%
5,478
+178
+3% +$18.9K
RVTY icon
160
Revvity
RVTY
$12.3B
$602K 0.01%
4,800
– –
GGG icon
161
Graco
GGG
$12.9B
$595K 0.01%
9,700
– –
CSGP icon
162
CoStar Group
CSGP
$11.3B
$594K 0.01%
7,000
– –
RDY icon
163
Dr. Reddy's Laboratories
RDY
$9.82B
$591K 0.01%
42,500
-142,500
-77% -$1.7M
ANSS
164
DELISTED
Ansys
ANSS
$590K 0.01%
1,802
– –
SQM icon
165
Sociedad Química y Minera de Chile
SQM
$19.6B
$590K 0.01%
18,200
– –
HTHT icon
166
Huazhu Hotels Group
HTHT
$12.4B
$584K 0.01%
13,500
– –
MCK icon
167
McKesson
MCK
$98.5B
$580K 0.01%
3,892
– –
MCO icon
168
Moody's
MCO
$81.7B
$580K 0.01%
2,000
– –
BF.B icon
169
Brown-Forman Class B
BF.B
$12B
$572K 0.01%
7,600
– –
TRMB icon
170
Trimble
TRMB
$12.3B
$570K 0.01%
11,700
– –
FDS icon
171
Factset
FDS
$9.05B
$569K 0.01%
1,700
– –
STNE icon
172
StoneCo
STNE
$2.62B
$566K 0.01%
+10,700
New +$511K
ENTG icon
173
Entegris
ENTG
$19.7B
$543K 0.01%
7,300
– –
MKC icon
174
McCormick & Company Non-Voting
MKC
$13.4B
$543K 0.01%
5,600
– –
MELI icon
175
Mercado Libre
MELI
$91.3B
$541K 0.01%
500
– –
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.